Want to see ABVC full AI Analyst Report?
ABVC Stock Chart & Stats
$2.10
-$0.06(-10.00%)
At close: 4:00 PM EST
$2.10
-$0.06(-10.00%)
Day’s Range― - ―
52-Week Range$0.88 - $5.48
Previous CloseN/A
Volume151.09K
Average Volume (3M)95.05K
Market Cap
$39.78M
Enterprise Value$22.30M
Total Cash (Recent Filing)$202.51K
Total Debt (Recent Filing)$2.73M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding26,000,443
10 Day Avg. Volume116,541
30 Day Avg. Volume95,045
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)4.46
Price to Sales (P/S)0.00
P/FCF Ratio-16.59
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue-28.01
Enterprise Value/Gross Profit-28.01
Enterprise Value/Ebitda-2.43
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.3
Revenue Forecast (FY)$35.28M
Bulls Say, Bears Say
Bulls Say
Partnering‑centric Business ModelABVC’s deliberate focus on out-licensing, partnerships and collaboration revenue is a durable model for clinical-stage biotech. It reduces the need to build commercial infrastructure, creates milestone/royalty upside, and preserves optionality to advance programs via partners.
Moderate Leverage And Asset BaseBalance-sheet leverage is moderate (D/E ~0.31) with a tangible asset base supporting operations. This capital structure offers more flexibility to raise incremental debt or secure partner-backed financing than a highly leveraged peer, lowering acute solvency risk over months.
Trailing Improvement In Cash BurnA sharp reduction in operating cash outflow in the TTM suggests the company has materially slowed cash burn or realized timing/receipts improvement. If sustained, this trend lengthens runway and reduces frequency of financing needs, improving execution optionality.
Bears Say
Persistent Unprofitability And Negative MarginsABVC reports recurring net losses and structurally negative operating margins driven by R&D and SG&A that overwhelm gross profit. Persistent losses erode equity, limit reinvestment capacity, and mean the company must rely on non-operating funding to sustain development programs.
Weak Cash Generation Across PeriodsNegative operating and free cash flow across periods indicate the business cannot self-fund development. Ongoing cash consumption increases liquidity risk, forces external financing, and constrains strategic choices, making long-term program advancement contingent on outside capital.
Dilution Risk From Equity Plan And Financing RelianceBoard-approved expanded equity incentives plus a history of capital-market funding mean shareholder dilution is a structural risk. With limited operating cash and no commercial revenue base, the company is likely to issue equity to fund programs, reducing existing owners' economic share.
ABVC BioPharma News
ABVC FAQ
What was ABVC BioPharma, Inc.’s price range in the past 12 months?
ABVC BioPharma, Inc. lowest stock price was $0.88 and its highest was $5.48 in the past 12 months.
What is ABVC BioPharma, Inc.’s market cap?
ABVC BioPharma, Inc.’s market cap is $39.78M.
When is ABVC BioPharma, Inc.’s upcoming earnings report date?
ABVC BioPharma, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 138 days.
How were ABVC BioPharma, Inc.’s earnings last quarter?
ABVC BioPharma, Inc. released its earnings results on Mar 27, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.11.
Is ABVC BioPharma, Inc. overvalued?
According to Wall Street analysts ABVC BioPharma, Inc.’s price is currently Overvalued.
Does ABVC BioPharma, Inc. pay dividends?
ABVC BioPharma, Inc. does not currently pay dividends.
What is ABVC BioPharma, Inc.’s EPS estimate?
ABVC BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABVC BioPharma, Inc. have?
ABVC BioPharma, Inc. has 26,000,443 shares outstanding.
What happened to ABVC BioPharma, Inc.’s price movement after its last earnings report?
ABVC BioPharma, Inc. reported an EPS of -$0.11 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.66%.
Which hedge fund is a major shareholder of ABVC BioPharma, Inc.?
Currently, no hedge funds are holding shares in ABVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ABVC BioPharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
447.44%
12-Months-Change
Fundamentals
Return on Equity
-92.03%
Trailing 12-Months
Asset Growth
32.65%
Trailing 12-Months
Company Description
ABVC BioPharma, Inc.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Technical Analysis
CervoMed
―
MindWalk Holdings
―
Jasper Therapeutics
―
MiNK Therapeutics
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
―
Insiders
1.39% Mutual Funds
0.04% Other Institutional Investors
97.69% Public Companies and
Individual Investors